BACKGROUND: Effector CD4+ T cell subsets play an important role in Multiple Sclerosis (MS). Interleukin-27 (IL-27) suppresses Th (Th1, Th2 and Th17) cells and dampens autoimmunity and tissue inflammation by promoting the generation of Type 1 regulatory T cells (Tr1). OBJECTIVE: To identify the relative levels of IL-27 and IL-17A in MS disease. METHOD: In a case-control study, venous blood was collected from forty MS patients and forty-three healthy subjects as control group. Serum levels of IL-27 and IL-17A were measured by ELISA method. RESULTS: A significant difference between serum IL-17A concentration in patients (120.68 ± 209.85 pg/ml) and control group (67.26 ± 117.76 pg/ml, p=0.016) was found. Serum IL-27 levels of the MS patients (159.7 ± 581.4 pg/ml) were significantly lower than control subjects (180.35 ± 507.84 pg/ml, p=0.001). CONCLUSION: Our findings show decreased levels of IL-27 against increasing IL-17A levels in patients group which may suggest a suppressive role of IL-27 on inflammatory process of MS.
BACKGROUND: Effector CD4+ T cell subsets play an important role in Multiple Sclerosis (MS). Interleukin-27 (IL-27) suppresses Th (Th1, Th2 and Th17) cells and dampens autoimmunity and tissue inflammation by promoting the generation of Type 1 regulatory T cells (Tr1). OBJECTIVE: To identify the relative levels of IL-27 and IL-17A in MS disease. METHOD: In a case-control study, venous blood was collected from forty MS patients and forty-three healthy subjects as control group. Serum levels of IL-27 and IL-17A were measured by ELISA method. RESULTS: A significant difference between serum IL-17A concentration in patients (120.68 ± 209.85 pg/ml) and control group (67.26 ± 117.76 pg/ml, p=0.016) was found. Serum IL-27 levels of the MS patients (159.7 ± 581.4 pg/ml) were significantly lower than control subjects (180.35 ± 507.84 pg/ml, p=0.001). CONCLUSION: Our findings show decreased levels of IL-27 against increasing IL-17A levels in patients group which may suggest a suppressive role of IL-27 on inflammatory process of MS.
Authors: Rakeshchandra R Meka; Shivaprasad H Venkatesha; Steven Dudics; Bodhraj Acharya; Kamal D Moudgil Journal: Autoimmun Rev Date: 2015-08-05 Impact factor: 9.754
Authors: Lars Börnsen; Jeppe Romme Christensen; Rikke Ratzer; Chris Hedegaard; Helle B Søndergaard; Martin Krakauer; Dan Hesse; Claus H Nielsen; Per S Sorensen; Finn Sellebjerg Journal: PLoS One Date: 2015-03-04 Impact factor: 3.240
Authors: Eddie Cano-Gamez; Blagoje Soskic; Theodoros I Roumeliotis; Ernest So; Deborah J Smyth; Marta Baldrighi; David Willé; Nikolina Nakic; Jorge Esparza-Gordillo; Christopher G C Larminie; Paola G Bronson; David F Tough; Wendy C Rowan; Jyoti S Choudhary; Gosia Trynka Journal: Nat Commun Date: 2020-04-14 Impact factor: 14.919